Abstract
THE MANAGEMENT OF anticoagulation for cardiopulmonary bypass (CPB) in patients with antiphospholipid antibodies is challenging because antiphospholipid antibodies increase the risk for arterial and venous thrombosis and affect commonly used in vitro coagulation assays such as the kaolin-activated coagulation time. 1 Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15: 145-151 Crossref PubMed Scopus (391) Google Scholar , 2 Asherson R.A. Khamashta M.A. Ordi-Ros J. et al. The primary antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore). 1989; 68: 366-374 Crossref PubMed Scopus (990) Google Scholar , 3 Finazzi G. Brancaccio V. Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med. 1996; 100: 530-536 Abstract Full Text PDF PubMed Scopus (395) Google Scholar , 4 Galli M. Finazzi G. Bevers E.M. et al. Kaolin clotting time and dilute Russell's viper venom time distinguish between pro-thrombin dependent and beta 2 glycoprotein I dependent antiphospholipid antibodies. Blood. 1995; 86: 617-623 PubMed Google Scholar
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
